The clinical role and cost-effectiveness of long-acting antiretroviral therapy

Clinical Infectious Diseases

Volumn 60, Issue 7, 2015, Pages 1102-1110

  Ross, Eric L ^a   Weinstein, Milton C ^b   Schackman, Bruce R ^c   Sax, Paul E ^d   Paltiel, A David ^e   Walensky, Rochelle P ^a,d   Freedberg, Kenneth A ^a,b,d,f   Losina, Elena ^a,d,f  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^c WEILL CORNELL MEDICAL COLLEGE   (United States)

^d BRIGHAM AND WOMEN S HOSPITAL   (United States)

^e YALE UNIVERSITY   (United States)

^f BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

cost effectiveness; HIV AIDS; long acting antiretroviral therapy; modeling

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ATAZANAVIR; DARUNAVIR; ENFUVIRTIDE; INTEGRASE INHIBITOR; MARAVIROC; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR; PROTEINASE INHIBITOR; VIRUS RNA; ANTIRETROVIRUS AGENT; DELAYED RELEASE FORMULATION;

ADULT; ARTICLE; COMPUTER SIMULATION; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HEALTH CARE COST; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIFE EXPECTANCY; LONG ACTING ANTIRETROVIRAL THERAPY; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; PATIENT COMPLIANCE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; SURVIVAL; TREATMENT DURATION; ADMINISTRATION AND DOSAGE; COHORT ANALYSIS; COST BENEFIT ANALYSIS; DELAYED RELEASE FORMULATION; ECONOMICS; HIV INFECTIONS; MIDDLE AGED; PROCEDURES; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; COHORT STUDIES; COMPUTER SIMULATION; COST-BENEFIT ANALYSIS; DELAYED-ACTION PREPARATIONS; FEMALE; HIV INFECTIONS; HUMANS; MALE; MIDDLE AGED; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84926658499     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu1159     Document Type: Article

References (42)

1. Walensky RP, Paltiel AD, Losina E, et al. The survival benefits of AIDS treatment in the United States. J Infect Dis 2006; 194:11-9.
2. Ray M, Logan R, Sterne JAC, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS 2010; 24:123-37.
3. Wood E, Hogg RS, Yip B, Harrigan PR, O'Shaughnessy MV, Montaner JSG. Effect ofmedication adherence on survival ofHIV-infected adultswho start highly active antiretroviral therapy when the CD4(+) cell count is 0.200 to 0.350 X 10(9) cells/L. Ann Intern Med 2003; 139:810-6.
4. Lima VD, Harrigan R, Bangsberg DR, et al. The combined effect of modern highly active antiretroviral therapy regimens and adherence on mortality over time. J Acquir Immune Defic Syndr 2009; 50:529-36.
5. Swindells S, Flexner C, Fletcher CV, Jacobson JM. The critical need for alternative antiretroviral formulations, and obstacles to their development. J Infect Dis 2011; 204:669-74.
6. Wu H, Yao C, Lu R, et al. Albuvirtide, the first long-Acting HIV fusion inhibitor, suppressed viral replication in HIV-infected adults [abstract H-554]. In: Program and abstracts of the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, CA, 2012. Available at: http://www.abstractsonline.com/Plan/ViewAbstract.aspx?. sKey=e1c18d5b-830f-4b4e-8671-35bcfb20eed5 & cKey=70d14bcc-bad6-4754-b4b1-66b7d2559a23 & mKey=%7B6B114A1D-85A4-4054-A83B-04D8B9B8749F%7D. Accessed 13 August 2014.
7. Verloes R, Van't Klooster G, Baert L, et al. TMC278 long acting-A parenteral nanosuspension formulation that provides sustained clinically relevant plasma concentrations in HIV-negative volunteers [abstract TUPE0042]. In: Program and abstracts of 17th International AIDS Conference, Mexico City, 2008. Available at: http://www.iasociety.org/Abstracts/A200717814.aspx. Accessed 13 August 2014.
8. Spreen W, Min S, Ford SL, et al. Pharmacokinetics, safety, and monotherapy antiviral activity of GSK1265744, an HIV integrase strand transfer inhibitor. HIV Clin Trials 2013; 14:192-203.
9. Baert L, van't Klooster G, Dries W, et al. Development of a long-Acting injectable formulation with nanoparticles of rilpivirine (TMC278) for HIV treatment. Eur J Pharm Biopharm 2009; 72:502-8.
10. Nowacek AS, Balkundi S, McMillan J, et al. Analyses of nanoformulated antiretroviral drug charge, size, shape and content for uptake, drug release and antiviral activities in human monocyte-derived macrophages. J Control Release 2011; 150:204-11.
11. Dash PK, Gendelman HE, Roy U, et al. Long-Acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 2012; 26: 2135-44.
12. Roy U, McMillan J, Alnouti Y, et al. Pharmacodynamic and antiretroviral activities of combination nanoformulated antiretrovirals in HIV-1-infected human peripheral blood lymphocyte-reconstituted mice. J Infect Dis 2012; 206:1577-88.
13. Van't Klooster G, Hoeben E, Borghys H, et al. Pharmacokinetics and disposition of rilpivirine (TMC278) nanosuspension as a long-Acting injectable antiretroviral formulation. Antimicrob Agents Chemother 2010; 54:2042-50.
14. Jackson AG, Else LJ, Mesquita PM, et al. A compartmental pharmacokinetic evaluation of long-Acting rilpivirine in HIV-negative volunteers for pre-exposure prophylaxis. Clin Pharmacol Ther 2014; 96:314-23.
15. Ford SL, Gould E, Chen S, et al. Lack of pharmacokinetic interaction between rilpivirine and integrase inhibitors dolutegravir and GSK1265744. Antimicrob Agents Chemother 2013; 57:5472-7.
16. ViiV Healthcare, GlaxoSmithKline. A study to investigate the safety, tolerability and pharmacokinetics of repeat dose administration of long-Acting GSK1265744 and long-Acting TMC278 intramuscular and subcutaneous injections in healthy adult subjects, 2013. Available at: http://clinicaltrials.gov/ct2/show/NCT01593046. Accessed 30 June 2014.
17. Freedberg KA, Losina E, Weinstein MC, et al. The cost effectiveness of combination antiretroviral therapy for HIV disease. N Engl J Med 2001; 344:824-31.
18. Schackman BR, Haas DW, Becker JE, et al. Cost-effectiveness analysis of UGT1A1 genetic testing to inform antiretroviral prescribing in HIV disease. Antivir Ther 2013; 18:399-408.
19. Walensky RP, Sax PE, Nakamura YM, et al. Economic savings versus health losses: the cost-effectiveness of generic antiretroviral therapy in the United States. Ann Intern Med 2013; 158:84-92.
20. Cutler D, Rosen A, Vijan S. The value of medical spending in the United States, 1960-2000. N Engl J Med 2006; 355:920-7.
21. Institute of Medicine. Hidden costs, value lost: uninsurance in America, 2003. Available at: http://www.iom.edu/Reports/2003/Hidden-Costs-Value-Lost-Uninsurance-in-America.aspx. Accessed 30 June 2014.
22. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the panel on cost-effectiveness in health and medicine. J Am Med Assoc 1996; 276:1253-8.
23. Noubary F, Hughes MD. Assessing agreement in the timing of treatment initiation determined by repeated measurements of novel versus gold standard technologies with application to the monitoring of CD4 counts in HIV-infected patients. Stat Med 2010; 29:1932-46.
24. Althoff KN, Gange SJ, Klein MB, et al. Late presentation for human immunodeficiency virus care in the United States and Canada. Clin Infect Dis 2010; 50:1512-20.
25. Daar ES, Tierney C, Fischl MA, et al. Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1. Ann Intern Med 2011; 154:445-56.
26. Hirsch JD, Gonzales M, Rosenquist A, Miller TA, Gilmer TP, Best BM. Antiretroviral therapy adherence, medication use, and health care costs during 3 years of a community pharmacy medication therapy management program for Medi-Cal beneficiaries with HIV/AIDS. J Manag Care Pharm 2011; 17:213-23.
27. Sax PE, Meyers JL, Mugavero M, Davis KL. Adherence to antiretroviral treatment and correlation with risk of hospitalization among commercially insured HIV patients in the United States. PLoS One 2012; 7: e31591.
28. Messou E, Chaix M-L, Gabillard D, et al. Association between medication possession ratio, virologic failure and drug resistance in HIV-1-infected adults on antiretroviral therapy in Cote d'Ivoire. J Acquir Immune Defic Syndr 2011; 56:356-64.
29. Red Book online, 2012. Available at: http://www.redbook.com/redbook/online/. Accessed 13 August 2014.
30. Fleishman JA, Yehia BR, Moore RD, Korthuis PT, Gebo KA. Establishment, retention, and loss to follow-up in outpatient HIV care. J Acquir Immune Defic Syndr 2012; 60:249-59.
31. Helleberg M, Engsig FN, Kronborg G, et al. Retention in a public healthcare system with free access to treatment: a Danish nationwide HIV cohort study. AIDS 2012; 26:741-8.
32. Centers for Disease Control and Prevention. HIV surveillance report: diagnosis of HIV infection in the United States and dependent areas, 2011, 2011. Available at: http://www.cdc.gov/hiv/pdf/statistics-2011-HIV-Surveillance-Report-vol-23.pdf#Page=17. Accessed 23 October 2014.
33. Department of Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2014. Available at: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadoles centgl.pdf. Accessed 23 October 2014.
34. Department of Health and Human Services. Medicaid drug price comparisons: average manufacturer price to published prices, 2005. Available at: http://oig.hhs.gov/oei/reports/oei-05-05-00240.pdf. Accessed 13 August 2014.
35. Bangsberg DR, Ragland K, Monk A, Deeks SG. A single tablet regimen is associated with higher adherence and viral suppression than multiple tablet regimens in HIV plus homeless and marginally housed people. AIDS 2010; 24:2835-40.
36. Lennox JL, DeJesus E, Berger DS, et al. Raltegravir versus efavirenz regimens in treatment-naive HIV-1-infected patients: 96-week efficacy, durability, subgroup, safety, and metabolic analyses. J Acquir Immune Defic Syndr 2010; 55:39-48.
37. Berg KM, Litwin AH, Li X, Heo M, Arnsten JH. Lack of sustained improvement in adherence or viral load following a directly observed antiretroviral therapy intervention. Clin Infect Dis 2011; 53:936-43.
38. Centers for Disease Control and Prevention. National HIV prevention progress report, 2013, 2013. Available at: http://www.cdc.gov/hiv/pdf/policies-NationalProgressReport.pdf. Accessed 30 June 2014.
39. Genberg BL, Wilson IB, Bangsberg DR, et al. Patterns of antiretroviral therapy adherence and impact on HIV RNA among patients in North America. AIDS 2012; 26:1415-23.
40. Parienti J-J, Das-Douglas M, Massari V, et al. Not all missed doses are the same: sustained NNRTI treatment interruptions predict HIV rebound at low-To-moderate adherence levels. PLoS One 2008; 3:810-6.
41. Wilson IB, Bangsberg DR, Shen J, et al. Heterogeneity among studies in rates of decline of antiretroviral therapy adherence over time: results from the Multisite Adherence Collaboration on HIV 14 study. J Acquir Immune Defic Syndr 2013; 64:448-54.
42. Simoni JM, Huh D, Wilson IB, et al. Racial/ethnic disparities in ART adherence in the United States: findings from the MACH14 study. J Acquir Immune Defic Syndr 2012; 60:466-72.